Protocol is not adapted to cancer pancreas disease as progression is very fast and patients stopped the study before 1st study assessment

The purpose of this study is to determine whether evolution of resting energetic expenditure is a predictive marker of tumoral response for patients suffering from metastatic pancreatic cancer and treated with 1st line of chemotherapy.

Inclusion Criteria:

• Pancreatic metastatic cancer
• Patient older than 18 years
• Initiation of a first line of chemotherapy by Folfirinox, or Gemcitabine or in combination with Nab-Paclitaxel.
• At least one measurable target lesion
• Patient signed consent for Energie-Pancreas study participation

Exclusion Criteria:

• Other concomitant cancer
• Major general status alteration ( Performance status = 3 or 4 at inclusion)
• Concomitant diseases explaining an altered general status or having an impact on energetic expenditure (i.e.chronic or severe infection, severe cardiac insufficiency, severe respiratory insufficiency, chronic inflammatory disease, recent surgery (< 1 month), ongoing Healing, hyperthyroidism.
• Smoker
• Patient deprived of his liberty, under guardianship, curator.
• Pregnant patient or breastfeeding
• Claustrophobic patient